Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

Web Exclusives - FDA Updates, Hepatocellular Carcinoma

On May 29, 2020, the FDA approved the combination of 2 immunotherapies, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, and bevacizumab (Avastin; Genentech), a vascular endothelial growth factor inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received systemic therapy.

Atezolizumab and bevacizumab have each previously been approved as monotherapy or in combination with other therapies for multiple indications. This is their first indication for HCC, and this is the first immunotherapy regimen approved by the FDA for first-line treatment of unresectable or metastatic HCC. Sorafenib (Nexavar), a kinase inhibitor, is currently the standard of therapy for first-line treatment of unresectable or metastatic HCC. It is estimated that more than 42,000 Americans will be diagnosed with liver cancer in 2020. HCC accounts for approximately 75% of all liver cancer cases in the United States.

“The results of the IMbrave150 study are really transformative for patients with advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Richard S. Finn, MD, Professor of Medicine, David Geffen School of Medicine, UCLA, and Director, Signal Transduction and Therapeutics Program, UCLA Jonsson Comprehensive Cancer Center. “For the first time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile.”

The FDA approved atezolizumab and bevacizumab for advanced HCC based on results from the phase 3 IMbrave150 clinical trial, a multicenter, open-label study that included 501 patients with unresectable or metastatic HCC who had not received systemic therapy. Patients were randomized in a 2:1 ratio to a combination of intravenous (IV) atezolizumab 1200 mg administered on day 1 of each 21-day cycle, plus IV bevacizumab 15 mg/kg administered on day 1 of each 21-day cycle (N = 336), or to monotherapy with oral sorafenib 400 mg, taken twice daily on days 1 to 21 of each 21-day cycle.

The study’s primary end points were overall survival (OS) and progression-free survival (PFS) as evaluated by an independent review facility per Response Evaluation Criteria in Solid Tumors version 1.1. Patients received the combination immunotherapy or sorafenib (N = 165) until disease progression or unacceptable toxicity.

The combination of atezolizumab and bevacizumab improved OS by 42% (hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.42-0.79; P = .001). The median PFS was 6.8 months (95% CI, 5.7-8.3) versus 4.3 months (95% CI, 4.0-5.6), for a reduction in PFS or death by 41% (HR, 0.59; 95% CI, 0.47-0.76; P <.0001) compared with sorafenib. At 12 months, the OS was 67.5% (95% CI, 61.3-73.1) with atezolizumab plus bevacizumab versus 54.6% (95% CI, 45.2-64) with sorafenib.

IMbrave150 is the first phase 3 immunotherapy study to show an improvement in OS and PFS in patients with unresectable or metastatic HCC compared with sorafenib.

The most common (≥2%) serious adverse reactions with the immunotherapy combination were gastrointestinal bleeding, infections, and fever.

Grade 3 or 4 adverse events occurred in 56.5% of those who received the immunotherapy combination and in 55.1% of the patients who received sorafenib. The rate of grade 3 or 4 hypertension was 15.2% with the immunotherapy combination.

Related Items
FDA News: June 22, 2022, and August 11, 2022.
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in FDA Updates
FDA News: April 1, 2022, and May 27, 2022
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in FDA Updates
FDA NEWS: February 28, 2022 to March 31, 2022
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in FDA Updates
FDA NEWS: January 10, 2022, and January 25, 2022
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in FDA Updates
FDA NEWS: November 29, 2021, and December 15, 2021
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in FDA Updates
FDA NEWS: August 13, 2021 to September 22, 2021
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in FDA Updates
FDA Issues Revised Final Guidance on Biosimilar Development and the BPCI Act
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in FDA Updates, Biosimilars
FDA NEWS: June 30, 2021, and July 26, 2021
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in FDA Updates
FDA NEWS: May 5, 2021 to May 28, 2021
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in FDA Updates
FDA NEWS: April 13, 2021 to April 23, 2021
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in FDA Updates
Last modified: July 22, 2021